We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Pacific Edge is a diagnostics & research business based in Australia. Pacific Edge shares (PEB) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Pacific Edge has a trailing 12-month revenue of around $11.5 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Overall broker
Our top pick for
Low-cost broker
| 52-week range | $0.72 - $1.605 |
|---|---|
| 50-day moving average | $0.817 |
| 200-day moving average | $1.0976 |
| Target price | N/A |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.02 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.64
| 1 week (2022-06-29) | 3.23% |
|---|---|
| 1 month (2022-06-07) | -3.03% |
| 3 months (2022-04-06) | -31.18% |
| 6 months (2022-01-06) | -48.18% |
| Revenue TTM | $11.5 million |
|---|---|
| Gross profit TTM | $3.5 million |
| Return on assets TTM | -16.16% |
| Return on equity TTM | -26.02% |
| Profit margin | -139.9% |
| Book value | 0.118 |
| Market capitalisation | $599 million |
TTM: trailing 12 months
We're not expecting Pacific Edge to pay a dividend over the next 12 months.
Over the last 12 months, Pacific Edge's shares have ranged in value from as little as $0.72 up to $1.605. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Pacific Edge's is 0.8049. This would suggest that Pacific Edge's shares are less volatile than average (for this exchange).
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, Singapore, and internationally. It operates in two segments, Commercial and Research. The company offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. It is also developing Cxbladder Resolve, a product designed to identify high grade or late stage bladder cancer and provide increased clinical resolution; Cxbladder Triage, a product that analyses the gene expression of urine-based biomarkers alongside information on known bladder cancer risk factors like age, gender, and smoking history to rule out patients with a low risk of having the disease; Cxbladder Detect that can be used as an adjunct to cystoscopy or as a substitute for other urine-based tests or imaging procedures; and Cxbladder Monitor, which is a non-invasive and easy-to-use test to rule out the return of bladder cancer. In addition, the company is developing Cxcolorectal (prognosis Gen II), a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancers; and products for bladder, gastric, colorectal, endometrial cancers, and melanoma. The company was incorporated in 2001 and is headquartered in Dunedin, New Zealand.
Steps to owning and managing Nordic Nickel shares.
Steps to owning and managing Dusk shares.
Everything we know about the Octava Minerals IPO, plus information on how to buy in.
Everything we know about the Australia Sunny Glass Group IPO, plus information on how to buy in.
Steps to owning and managing Kincora Copper shares.
Everything we know about the Dragon Mountain Gold IPO, plus information on how to buy in.
Steps to owning and managing Arcadia Minerals shares.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
